Raymond James Financial
REGN icon

Raymond James Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Raymond James Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128M Buy
165,542
+15,932
+11% +$12.2M 0.04% 420
2025
Q4 		$115M Buy
149,610
+11,104
+8% +$7.54M 0.04% 449
2025
Q3 		$77.9M Buy
138,506
+7,455
+6% +$4.22M 0.03% 584
2025
Q2 		$68.8M Buy
131,051
+19,542
+18% +$10.9M 0.02% 604
2025
Q1 		$70.7M Buy
111,509
+20,006
+22% +$13.8M 0.03% 557
2024
Q4 		$65.2M Buy
+91,503
New +$76.8M 0.02% 593

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Raymond James Financial's REGN Position: Q1 2026 in Review

Raymond James Financial increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, buying an estimated $12.2M and bringing the position to 165,542 shares worth $128M. The position accounts for 0.04% of the portfolio, ranked #420.

Raymond James Financial first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Raymond James Financial held 165,542 shares of Regeneron Pharmaceuticals worth $128M as of Q1 2026.
  • Raymond James Financial bought 15,932 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $12.2M.
  • Regeneron Pharmaceuticals made up 0.04% of Raymond James Financial's portfolio in Q1 2026, its #420 holding.
  • Raymond James Financial first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.